Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Research & Development (2016 - 2025)

Seres Therapeutics' Research & Development history spans 11 years, with the latest figure at $12.6 million for Q3 2025.

  • For Q3 2025, Research & Development rose 3.56% year-over-year to $12.6 million; the TTM value through Sep 2025 reached $50.2 million, down 28.8%, while the annual FY2024 figure was $64.6 million, 45.07% down from the prior year.
  • Research & Development for Q3 2025 was $12.6 million at Seres Therapeutics, down from $12.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $46.8 million in Q2 2023 and bottomed at -$17.0 million in Q4 2022.
  • The 5-year median for Research & Development is $23.0 million (2023), against an average of $24.6 million.
  • The largest annual shift saw Research & Development plummeted 146.39% in 2022 before it soared 235.16% in 2023.
  • A 5-year view of Research & Development shows it stood at $36.8 million in 2021, then plummeted by 146.39% to -$17.0 million in 2022, then skyrocketed by 235.16% to $23.0 million in 2023, then crashed by 44.27% to $12.8 million in 2024, then decreased by 1.75% to $12.6 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Research & Development are $12.6 million (Q3 2025), $12.9 million (Q2 2025), and $11.8 million (Q1 2025).